Rabbit MEPE (Matrix Extracellular Phosphoglycoprotein) ELISA Kit
- Known as:
- Rabbit MEPE (Matrix Extracellular Phosphoglycoprotein) Enzyme-linked immunosorbent assay test Kit
- Catalog number:
- e-el-rb2045
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Elabscience
- Gene target:
- Rabbit MEPE (Matrix Extracellular Phosphoglycoprotein) ELISA Kit
Related genes to: Rabbit MEPE (Matrix Extracellular Phosphoglycoprotein) ELISA Kit
- Gene:
- MEPE NIH gene
- Name:
- matrix extracellular phosphoglycoprotein
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 4q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 2000-09-19
- Date modifiied:
- 2016-10-05
Related products to: Rabbit MEPE (Matrix Extracellular Phosphoglycoprotein) ELISA Kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size"0" Calibrator Matrix, Liquid 20ml Vial"0" Calibrator Matrix, Liquid 20ml Vial(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit Related articles to: Rabbit MEPE (Matrix Extracellular Phosphoglycoprotein) ELISA Kit
- The mechanisms underlying sex differences in calcific aortic valve stenosis (CAVS) are poorly understood. We aimed to uncover sex-specific gene expression signatures of CAVS, including genes located on sexual chromosomes. - Source: PubMed
Publication date: 2026/05/22
Houessou UrsulaZamani PardisManikpurage Hasanga DLi ZhonglinGaudreault NathalieDahmene ManelDagenais FrançoisCouture ChristianClavel Marie-AnnickPibarot PhilippeMathieu PatrickBossé YohanThériault Sébastien - Osteocytes play a major role in the regulation of bone remodelling and homeostatis and should therefore be more prominently incorporated into in vitro bone models. Bioprinting is a versatile method to generate spatially defined tissue-like structures, however bioprinting of osteocytes remains challenging due to their post-mitotic nature. This study therefore investigates the transition of primary human osteoblasts (hOB) into osteocytes in bioprinted constructs, with respect to bioink composition and growth factor supplementation. Osteocytes were successfully differentiated from hOB, within bioprinted constructs via using alginate/methylcellulose/gelatin ink, alginate/methylcellulose/egg white ink and alginate/methylcellulose/human plasma ink (Alg/MC/Pl). Osteocytic morphology and marker expression was confirmed by fluorescence microscopy and gene expression analysis. Moreover, a significant upregulation of late osteocytic markers (e.g. SOST and MEPE) was observed under low serum conditions (2%) compared with cultures maintained in 10 % fetal calf serum (FCS). Human platelet lysate (hPL), evaluated as an alternative to FCS, also demonstrated the capacity to support osteocyte differentiation. Furthermore, hPL was successfully used for hOB pre-differentiation. In the presence of 2 % hPL, a higher number of multinucleated osteoclasts along with an elevated activity of osteoclast-specific enzymes (tartrate-resistant acid phosphatase, cathepsin K and carbonic anhydrase 2) in comparison to 2 % FCS was observed. This high potential of hPL to support osteoclastogenesis opens the way for physiologically-relevant in vitro bone models comprising both osteocytes and osteoclasts. Indirect co-cultures of human osteoclasts and human osteocytes, bioprinted and differentiated in Alg/MC/Pl showed expression of all relevant osteoclast and osteocyte markers.
. - Source: PubMed
Publication date: 2026/05/27
Bernhardt AnneLiu SuihongKara Özenler AylinWirsig KatharinaGelinsky Michael - The increasing prevalence of bone-related diseases and the desire to improve patient outcomes are driving research into bone replacement materials that overcome the limits of current bone substitutes. Molybdenum (Mo) is a promising candidate as an implant and degradable bone replacement material because it combines three key properties: mechanical strength, biocompatibility, and resorbability. However, little is known about the cellular mechanisms induced by Mo on bone regeneration. This study exposed a complex in vitro bone model as quadruple culture with primary human osteoblasts, osteocytes, osteoclasts, and endothelial cells, to Mo powder extracts to understand cell-material interactions in a multicellular system. Extracts with a final concentration of 1 mM Mo in quadruple cultures induced osteogenic differentiation by stimulation of gene expression and ALP activity, and gene expression, as well as enhanced calcium deposition of osteoblasts. Furthermore, expression of osteoblasts increased significantly and network formation of HUVEC with stimulated expression occurred. However, CD31 () expression and endothelial network density were reduced, indicating a complex, mixed angiogenic response. In contrast, Mo inhibited osteoclast formation and slowed down osteocyte differentiation, reducing , , and gene expression. Additionally, the RANKL ()/OPG () ratio of osteocytes was shifted toward OPG after Mo treatment. Cellular effects are most likely caused by the presence of molybdate anions. In summary, Mo extracts stimulated early bone healing factors involved in osteogenesis, vascularization, and mineralization, while osteoclastogenesis was inhibited. These dual effects in vitro provide mechanistic evidence supporting the potential of Mo as a growth factor-free bone replacement material and establish a cellular foundation for further preclinical development. - Source: PubMed
Publication date: 2026/05/07
Wirsig KatharinaBernhardt Anne - The efficacy of current bone-targeting agents, notably bisphosphonates, in the treatment of bone metastases remains limited by their systemic toxicity and excessively long half-life. This study aims to develop bone-targeting agents inspired by osteotropic peptides involved in the bone mineralization process. These agents are intended to provide an innovative alternative to bisphosphonates for precision bone targeting. - Source: PubMed
Publication date: 2026/04/26
Jamous MazenRoether BarbaraMühlberg EricKleist ChristianKübelbeck ArminHaberkorn UweMier Walter - Effective management of cutaneous wounds is challenging in clinical practice. The present study aimed to investigate the relative efficacy and explore the potential differences of nanostructured propolis ointment, platelet rich plasma (PRP) and their combination in enhancing the healing of experimentally induced cutaneous defect in dog model. The study included 6 dogs with 6 skin wounds per dog. A 3-cm full-thickness skin wounds were surgically induced on the lateral thoracic walls. Wounds were randomly allocated to six treatment groups: control, lanolin (vehicle), nano-propolis, PRP, PRP-lanolin, and PRP-nano-propolis. Wound healing progression was evaluated clinically and histologically over 20 days using wound area measurements, epithelization, granulation tissue formation, and collagen deposition. The tumor necrosis factor-alpha (TNF-α) was immunohistochemically assessed. Biochemical markers including total antioxidant capacity (TAC), malondialdehyde (MDA), matrix extracellular phosphoglycoprotein (MEPE), transforming growth factor beta (TGF-β), platelet growth factor beta (PDGF-β) levels were also evaluated. - Source: PubMed
Publication date: 2026/03/21
Wafy Mona NHassan Elham ASaeed SamarKhattab Marwa SAbuBakr Huda OYassin Aya MAbu-Seida Ashraf M